Actinium Pharmaceuticals
ATNM
#10401
Rank
A$64.38 M
Marketcap
A$2.05
Share price
-3.38%
Change (1 day)
-2.86%
Change (1 year)

Earnings for Actinium Pharmaceuticals (ATNM)

Earnings in 2026 (TTM): A$13.15 Million

According to Actinium Pharmaceuticals's latest financial reports the company's current earnings are A$35.09 Million. In 2025 the company made an earning of -A$51.91 Million, an increase over its 2024 earnings that were of -A$60.33 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Actinium Pharmaceuticals from 2007 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$13.15 M-125.35%
2025 -A$51.91 Million-13.95%
2024 -A$60.33 Million-18.87%
2023 -A$74.36 Million52.24%
2022 -A$48.85 Million36.61%
2021 -A$35.76 Million11.48%
2020 -A$32.07 Million1.46%
2019 -A$31.61 Million-7.37%
2018 -A$34.13 Million-11.46%
2017 -A$38.54 Million10.67%
2016 -A$34.83 Million15.7%
2015 -A$30.1 Million-14.86%
2014 -A$35.36 Million129.19%
2013 -A$15.43 Million-8.55%
2012 -A$16.87 Million
2010 A$0.01 M-152.15%
2009 -A$0.03 Million-39.8%
2008 -A$0.04 Million120.29%
2007 -A$0.02 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Genocea Biosciences
GNCA
-A$53.27 Million-489.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
A$0.27 M-98.00%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$0.21 B 1,460.38%๐Ÿ‡บ๐Ÿ‡ธ USA